FDAClass IOctober 15, 2025

NAD+ (Nicotinamide adenine dinucleotide) for Injection recall: Endotoxin

NAD+ (Nicotinamide adenine dinucleotide) for Injection, a) 100 mg/mL b) 200 mg/mL, 10 mL multi-dose amber vials, GenoGenix, LLC, 2840 NW 2nd Ave Ste…

Why was NAD+ (Nicotinamide adenine dinucleotide) for Injection recalled?

Microbial Contamination of Sterile Products: elevated endotoxin levels

What should I do if I have this product?

The recall is ongoing. Follow the firm and FDA instructions.

What to do with a recalled product: refunds, receipts, safe disposal and how to report a problem.

Is my product affected?

Compare the item in your hand with every identifier below from the official FDA record. Only products that match the listed product and lot, UPC or model codes are part of this recall.

Which lot codes, UPCs or models are affected?

Lot#: GG121624-023, within expiry

Product
NAD+ (Nicotinamide adenine dinucleotide) for Injection, a) 100 mg/mL b) 200 mg/mL, 10 mL multi-dose amber vials, GenoGenix, LLC, 2840 NW 2nd Ave Ste…
Recalling firm
GenoGenix LLC
Distribution
US Nationwide.
Recall date
October 15, 2025
Classification
Class I
Status
Ongoing
Agency
FDA (drug)
Open FDA enforcement record Latest recalls